Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03780517
Title	Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors
Recruitment	Completed
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	Boston Pharmaceuticals
Indications	Advanced Solid Tumor lung non-small cell carcinoma thyroid gland medullary carcinoma
Therapies	DS-5010
Age Groups:	senior \| adult
Covered Countries	USA \| FRA \| ESP \| BEL